Company profile for Silverback Therapeutics

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Silverback Therapeutics is charting a new path for treating a range of severe diseases. We are developing therapies that act on fundamental biological pathways that underlie disease, but that modern medicine has not been able to fully harness — until now. Our team brings together diverse perspectives and deep experience in drug discovery and development, allowing us to approach long-standing challenges in new ways. At the...
Silverback Therapeutics is charting a new path for treating a range of severe diseases. We are developing therapies that act on fundamental biological pathways that underlie disease, but that modern medicine has not been able to fully harness — until now. Our team brings together diverse perspectives and deep experience in drug discovery and development, allowing us to approach long-standing challenges in new ways. At the core of our pipeline is our proprietary ImmunoTAC™ technology, which is designed to create potent therapeutic molecules that can be systemically administered to patients.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
U.S.A
Address
Address
500 Fairview Ave N #600 Seattle, WA 98109 (206) 456-2900
Telephone
Telephone
Linkedin
Linkedin
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Tides Asia

Tides Asia

Not Confirmed

envelop Contact Supplier

Tides Asia

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.biospace.com/article/releases/ars-pharmaceuticals-closes-merger-with-silverback-therapeutics/?s=79

BIOSPACE
08 Nov 2022

https://www.businesswire.com/news/home/20221021005114/en

BUSINESSWIRE
21 Oct 2022

https://www.fiercepharma.com/pharma/silverback-admits-defeat-ars-troops-forward-fund-commercialization-epinephrine-nasal-spray

Nick Paul Taylor FIERCEPHARMA
27 Jul 2022

 https://www.businesswire.com/news/home/20220721005023/en/Silverback-Therapeutics-and-ARS-Pharmaceuticals-Announce-Merger

BUSINESSWIRE
21 Jul 2022

https://www.businesswire.com/news/home/20220517005953/en

BUSINESSWIRE
17 May 2022

https://www.businesswire.com/news/home/20220512005266/en

BUSINESSWIRE
12 May 2022

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty